Clinical Trial

SUNRISE Aims to Create a Comprehensive, Engaging, and Sustainable Digital Health Promotion Program That Not Only Addresses Immediate Health Behaviours But Also Instils Lifelong Healthy Habits Among Adolescents. It is a Unique, Digitally Enhanced Program Combining Different Digital Solutions With New

Study acronym: SUNRISE_2
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
SUNRISE aims to create a comprehensive, engaging, and sustainable digital health promotion program that not only addresses immediate health behaviours but also instills lifelong healthy habits among adolescents. By integrating cutting-edge digital tools with traditional educational settings, SUNRISE seeks to bridge the gap between knowledge and practice, making cancer prevention a tangible and achievable goal for young people. This study represents a significant step towards reducing the future burden of cancer through early and innovative preventive measures. The SUNRISE project aims to test its interventions on students across eight European countries, including Greece, Switzerland, Slovenia, Spain, Cyprus, Italy, Belgium, and Romania. This study focuses on integrating a unique, digitally enhanced program combining different digital solutions with new methods to change adolescent health behaviour through social media campaigns, social bot platforms, educational games, and health-related advertising content into the school environment, targeting students aged 10 to 19 years. The program emphasizes inclusivity, ensuring participation from both urban and rural regions and socially disadvantaged groups such as ethnic minorities and migrants. By addressing diverse socio-economic, cultural, and environmental contexts, SUNRISE aspires to create a universally applicable and impactful intervention.
Trial Details
NCT Number NCT06931847
Lead Sponsor Biobizkaia Health Research Institute
Collaborators: FEDERAZIONE ITALIANA DELLE ASSOCIAZIONI DI VOLONTARIATO IN ONCOLOGIA, Hellenic Mediterranean University, University Ghent, University of Zurich, FISABIO (Foundation for the Promotion of Healthcare and Biomedical Research in the Valencian Community), The Oncology Institute "Prof. Dr. Ion Chiricuţă" Cluj-Napoca, Cyprus Association of Cancer Patients and Friends (PASYKAF), Alma Mater Europaea - Slovenia
Conditions Cancer
Enrollment 4,000 participants
Start Date 2025-09
Primary Completion 2027-03 (estimated)
Study Completion 2028-04 (estimated)
Updated on ClinicalTrials.gov 2025-04-17